surmount-1 tirzepatide weight loss percent 72 weeks after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial Tirzepatide for Obesity: Highlights from

One of the most common themes is surprisingly consistent: many patients prefer staying on the lowest dose that continues working rather than increasing automatically every month

Some choose to stay at 10 mg long-term rather than continuing to higher doses

Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial

I havent had any issues with reaching customer servic

The most common GLP-1 side effects are nausea, fatigue, and constipation, particularly during the first 46 weeks of dose escalation

This study used only de-identified patient records and did not involve the collection, use, or transmittal of individually identifiable data